EBRCZ
EBR SYSTEMS INC NPV CDI 1:10.6037
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
351.79MP/E (TTM)
-Basic EPS (TTM)
-0.12Dividend Yield
0%Recent Filings
8-K
Q4 implants double, revenue previewed
EBR Systems doubled WiSE System implants to 18 in Q4 2025 versus Q3, hitting 30 total in pilot and limited release, while signing 9 more purchase agreements and training 11 physicians. Preliminary unaudited revenue hit US$870K–935K for the quarter, US$1.552M–1.617M for the year. Momentum builds. WiSE-UP and TLC-AU studies kicked off with initial enrollments, but figures await audit.
10-Q
Q3 FY2025 results
EBR Systems posted Q3 revenue of $512K, up from zero a year ago after FDA approval of WiSE CRT in April 2025, with gross margin at 43.8%. Operating loss widened to $11.9M from $9.2M y/y, driven by SG&A jumping to support sales ramp-up, while R&D dipped slightly; net loss hit $12.2M or $(0.03) per share on 450M diluted shares. Cash swelled to $12.6M plus $58M marketable securities, bolstered by $46M from stock issuance, against $41.8M debt due 2027. Inventory built to $11.2M for commercialization. Post-marketing study starts November 2025.
10-Q
Q2 FY2025 results
EBR Systems notched its first revenue in Q2 FY2025, posting $169,704 from WiSE CRT System sales—up from zero last year—thanks to April's FDA approval for U.S. commercial use in tough cardiac cases. Gross margin hit 50.0%, though excluding prior clinical inventory it'd dip negative; operating loss widened to $11.1M from $10.7M y/y, driven by SG&A jumps for sales ramp-up, while R&D eased on lower manufacturing costs. Net loss climbed to $12.0M, or $0.03/share, versus $11.5M last year, with the gap tied to interest and forex hits. Cash swelled to $45.0M plus $39.6M in marketable securities after $46.2M from stock raises, against $40.6M debt due 2027 at prime +4.9%; free cash flow not disclosed in the 10-Q. FDA post-approval studies loom large.
8-K
EBR raises $36M via CDI placement
EBR Systems raised U.S. $36.0 million through an institutional placement of 55,900,000 CDIs at A$1.00 each on the ASX, settled May 26, 2025, after deducting $2.2 million in fees. The fully underwritten deal bolsters the company's cash position for ongoing operations. Yet dilution hits existing shareholders hard.
8-K
EBR approves governance upgrades
EBR Systems stockholders approved key governance measures at their May 21, 2025 annual meeting, including an amendment to the Certificate of Incorporation limiting officer liability under Delaware law, filed May 22. They ratified a prior issuance of 45,568,852 CDIs at A$0.82 each and endorsed amendments to the 2021 Equity Incentive Plan plus option grants totaling US$1,225,000 to executives and directors. This bolsters retention amid growth. No risks disclosed.
IPO
Employees
Sector
Industry
BWAY
Brainsway Ltd.
16.87-0.47
CBLL
CeriBell, Inc.
21.99+0.09
CVRX
CVRx, Inc.
8.32+0.14
ELMD
Electromed, Inc.
29.88+0.28
EMED
Electromedical Technologies, In
0.00+0.00
EW
Edwards Lifesciences Corporatio
85.32+1.94
HSCS
HeartSciences Inc.
2.31-0.16
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NPCE
Neuropace, Inc.
15.88-0.04
VTAK
Catheter Precision, Inc.
2.19-0.04